Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $495000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 23.44% to $495000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 7.86% decrease, with the full-year FY2025 number at $1.7 million, down 7.86% from a year prior.
  • Amortization of Deferred Charges was $495000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from $402000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $618000.0 in Q3 2023 to a low of $265000.0 in Q1 2023.
  • A 3-year average of $443250.0 and a median of $402000.0 in 2024 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 95.09% in 2024; the steepest drop was 35.11% in 2024.
  • Lexicon Pharmaceuticals' Amortization of Deferred Charges stood at $618000.0 in 2023, then plummeted by 35.11% to $401000.0 in 2024, then rose by 23.44% to $495000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Amortization of Deferred Charges are $495000.0 (Q4 2025), $402000.0 (Q3 2025), and $402000.0 (Q2 2025).